Recently, new dual agonists have received considerable attention for developing powerful drugs against diabetes. The strategy of dual agonists was aimed to treat both insulin resistance and dyslipidemia [12] . A critical challenge for developing dual agonists is how to identify the receptor subtype selectivity ratio [13] .